{"disease":{"id":"malignant-neoplasm","name":"Malignant Neoplasm","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":60},"drugs":{"marketed":[{"drug_id":"ibrance","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibrance","generic_name":"Palbociclib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":88,"revenue":"4500","mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"abemaciclib","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verzenio","generic_name":"abemaciclib","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/CDK6)","drug_class":"Kinase inhibitor","quality_score":78,"revenue":"3700","mechanism":"Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression."},{"drug_id":"lee011","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kisqali","generic_name":"LEE011","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinase 4","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"3600","mechanism":"Kisqali works by blocking a protein called cyclin-dependent kinase 4, which helps cancer cells grow and divide."},{"drug_id":"trastuzumab","indication_name":"Secondary malignant neoplasm of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"trastuzumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 receptor, subdomain IV","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"2900","mechanism":"HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells."},{"drug_id":"trastuzumab","indication_name":"Secondary malignant neoplasm of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"trastuzumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 receptor, subdomain IV","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"2900","mechanism":"HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells."},{"drug_id":"bevacizumab","indication_name":"Malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"bevacizumab","indication_name":"Malignant neoplasm of colon and/or rectum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"bevacizumab","indication_name":"Secondary malignant neoplasm of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"ramucirumab","indication_name":"Malignant neoplasm of colon and/or rectum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyramza","generic_name":"RAMUCIRUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]","quality_score":10,"revenue":"900","mechanism":"Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread."},{"drug_id":"everolimus","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"exemestane","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromasin","generic_name":"exemestane","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase Inhibitor [EPC]","quality_score":81,"revenue":"450","mechanism":"Aromasin works by blocking the aromatase enzyme, which is responsible for converting androgens into estrogens."},{"drug_id":"nabpaclitaxel","indication_name":"Secondary malignant neoplasm of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"nab-paclitaxel","indication_name":"Secondary malignant neoplasm of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"paclitaxel","indication_name":"Secondary malignant neoplasm of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"pemigatinib","indication_name":"Malignant neoplasm of common bile duct (& [carcinoma])","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pemazyre","generic_name":"PEMIGATINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"200","mechanism":"Pemazyre blocks the activity of the FGFR1 protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"zirabev","indication_name":"Malignant neoplasm of colon and/or rectum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"zirabev","indication_name":"Secondary malignant neoplasm of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"flox","indication_name":"Malignant neoplasm of liver","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLOX","company_name":"Hospira","drug_phase":"marketed","molecular_target":"Thymidylate synthase, Thymidylate synthase","drug_class":"","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"flox","indication_name":"Primary malignant neoplasm of gastrointestinal tract","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLOX","company_name":"Hospira","drug_phase":"marketed","molecular_target":"Thymidylate synthase, Thymidylate synthase","drug_class":"","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"aromasin","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aromasin","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Androgen receptor, Aromatase","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"pd-0332991","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PD-0332991","generic_name":"pd-0332991","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2","drug_class":"PD-0332991, 125mg, 3 cycles","quality_score":null,"revenue":null,"mechanism":"PD-0332991, 125mg, 3 cycles"},{"drug_id":"endometrin","indication_name":"Secondary malignant neoplasm of kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endometrin","generic_name":"progesterone","company_name":"Ferring","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"Progesterone [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"afinitor","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"testosteron","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosteron","company_name":"Gulhane School of Medicine","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-dkst","indication_name":"Secondary malignant neoplasm of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OGIVRI","generic_name":"TRASTUZUMAB-DKST","company_name":"MYLAN GMBH","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"trastuzumab-dkst","indication_name":"Secondary malignant neoplasm of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OGIVRI","generic_name":"TRASTUZUMAB-DKST","company_name":"MYLAN GMBH","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"oxymesterone","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anamidol","generic_name":"OXYMESTERONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"oxymesterone","quality_score":null,"revenue":null,"mechanism":"Anamidol binds to androgen receptors in the body, triggering a cascade of downstream effects that promote muscle growth and development."},{"drug_id":"fluoxymesterone","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluotestin","generic_name":"FLUOXYMESTERONE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ribociclib","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kisqali","generic_name":"ribociclib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme","drug_class":"CDK4/6 inhibitor; aromatase inhibitor","quality_score":61,"revenue":null,"mechanism":"Ribociclib inhibits CDK4/6 kinases to arrest G1 cell cycle phase; letrozole inhibits aromatase to reduce estrogen biosynthesis."},{"drug_id":"anastrozole","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arimidex","generic_name":"anastrozole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aromatase enzyme","drug_class":"Aromatase inhibitor","quality_score":68,"revenue":null,"mechanism":"Anastrozole selectively inhibits aromatase enzyme, suppressing estrogen biosynthesis in postmenopausal breast cancer."},{"drug_id":"carmustin","indication_name":"Malignant neoplasm of brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carmustin","company_name":"University Hospital Freiburg","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"femara","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Femara","company_name":"M.D. Anderson Cancer Center","drug_phase":"discontinued","molecular_target":"Cytochrome P450 11B2, mitochondrial, Aromatase, Cytochrome P450 11B1, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"letrozole","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Femara","generic_name":"letrozole","company_name":"Novartis AG","drug_phase":"marketed","molecular_target":"aromatase enzyme","drug_class":"Aromatase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Letrozole reduces estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogens."},{"drug_id":"testosterone-cypionate-200mg-3ml","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Testosterone cypionate (200mg/3ml)","company_name":"Leticia Maria Defendi Barboza Marson","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgenic steroid","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"irinotecan","indication_name":"Secondary malignant neoplasm of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"irinotecan","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I","drug_class":"Topoisomerase Inhibitor","quality_score":76,"revenue":null,"mechanism":"Irinotecan and its metabolite SN-38 bind to the topoisomerase I-DNA complex, preventing DNA repair and causing double-strand breaks."},{"drug_id":"floxuridine","indication_name":"Malignant neoplasm of liver","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fudr","generic_name":"FLOXURIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"floxuridine","indication_name":"Primary malignant neoplasm of gastrointestinal tract","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fudr","generic_name":"FLOXURIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"megestrol-acetate","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Megace","generic_name":"MEGESTROL ACETATE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Progestin","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-hydrochloride","indication_name":"Secondary malignant neoplasm of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"Irinotecan Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Topoisomerase Inhibitor","quality_score":79,"revenue":null,"mechanism":"Camptosar works by blocking the enzyme topoisomerase I, which is necessary for DNA replication, thereby preventing cancer cells from dividing and growing."},{"drug_id":"aminoglutethimide","indication_name":"Secondary malignant neoplasm of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytadren","generic_name":"AMINOGLUTETHIMIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Adrenal Steroid Synthesis Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"trazimera","indication_name":"Secondary malignant neoplasm of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"Trastuzumab-Qyyp","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 (c-erbB2) proto-oncogene transmembrane receptor protein","drug_class":"HER2/neu receptor antagonist monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity."},{"drug_id":"trazimera","indication_name":"Secondary malignant neoplasm of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"Trastuzumab-Qyyp","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 (c-erbB2) proto-oncogene transmembrane receptor protein","drug_class":"HER2/neu receptor antagonist monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity."},{"drug_id":"apatinib","indication_name":"Secondary malignant neoplasm of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rivoceranib","generic_name":"Apatinib","company_name":"Zhongda Hospital","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"methyltestosterone","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testred","generic_name":"METHYLTESTOSTERONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"onivyde","indication_name":"Secondary malignant neoplasm of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"onivyde","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Topoisomerase Inhibitor","quality_score":74,"revenue":null,"mechanism":"Camptosar works by inhibiting topoisomerase I, an enzyme that helps DNA replicate, causing DNA damage and cancer cell death."},{"drug_id":"anastrazole","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Anastrazole","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"vectibix","indication_name":"Secondary malignant neoplasm of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"vectibix","company_name":"Centre Jean Perrin","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"herceptin","indication_name":"Secondary malignant neoplasm of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Herceptin","company_name":"National Cancer Institute (NCI)","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"herceptin","indication_name":"Secondary malignant neoplasm of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Herceptin","company_name":"National Cancer Institute (NCI)","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-herceptin","indication_name":"Secondary malignant neoplasm of female breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trastuzumab (Herceptin)","generic_name":"trastuzumab-herceptin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-herceptin","indication_name":"Secondary malignant neoplasm of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trastuzumab (Herceptin)","generic_name":"trastuzumab-herceptin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"progesteron","indication_name":"Secondary malignant neoplasm of kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Progesteron","company_name":"Minia University","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoladex","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoladex","company_name":"University of Michigan Rogel Cancer Center","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor, Lutropin-choriogonadotropic hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"megestrol","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"megestrol","company_name":"National Center for Research Resources (NCRR)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C9, Multidrug resistance protein 1, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Secondary malignant neoplasm of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"taxol","indication_name":"Secondary malignant neoplasm of pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"testosterone-enantate","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xyosted (Autoinjector)","generic_name":"testosterone enantate","company_name":"Endo","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"arimidex","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arimidex","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"doxifluridine","indication_name":"Primary malignant neoplasm of gastrointestinal tract","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flutron","generic_name":"DOXIFLURIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"doxifluridine","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"talaporfin","indication_name":"Primary malignant neoplasm of brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Laserphyrin","generic_name":"TALAPORFIN","company_name":"Meiji Seika Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"talaporfin","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"avastin","indication_name":"Malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avastin","indication_name":"Malignant neoplasm of colon and/or rectum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avastin","indication_name":"Secondary malignant neoplasm of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"drostanolone-propionate","indication_name":"Malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metholone","generic_name":"drostanolone propionate","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"drostanolone propionate","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"medroxyprogesterone","indication_name":"Secondary malignant neoplasm of kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Provera","generic_name":"medroxyprogesterone","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Progesterone receptor","drug_class":"Progestin","quality_score":null,"revenue":null,"mechanism":"Depo-Provera works by binding to the progesterone receptor in the body, which helps to regulate the menstrual cycle and prevent pregnancy."},{"drug_id":"carmustine","indication_name":"Malignant neoplasm of brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gliadel","generic_name":"CARMUSTINE","company_name":"Avet Lifesciences","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"Alkylating Drug","quality_score":10,"revenue":null,"mechanism":"Gliadel works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"testosterone","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Androgel","generic_name":"TESTOSTERONE","company_name":"Besins Hlthcare","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"goserelin","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zoladex","generic_name":"goserelin","company_name":"Tersera","drug_phase":"marketed","molecular_target":"pituitary gonadotropin secretion","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":54,"revenue":null,"mechanism":"ZOLADEX inhibits pituitary gonadotropin secretion, leading to regression or inhibition of hormonally sensitive tumors."},{"drug_id":"goserelin-acetate","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zoladex","generic_name":"GOSERELIN ACETATE","company_name":"Tersera","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Agonist","quality_score":54,"revenue":null,"mechanism":"Zoladex works by mimicking the body's natural hormone to reduce testosterone production."},{"drug_id":"larotrectinib","indication_name":"Malignant Neoplasm","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitrakvi","generic_name":"LAROTRECTINIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"High affinity nerve growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Vitrakvi works by blocking the activity of a specific protein called the nerve growth factor receptor."},{"drug_id":"depo-testosterone","indication_name":"Hormone receptor positive malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Testosterone Cypionate","generic_name":"Testosterone Cypionate","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"zirabev","indication_name":"Malignant neoplasm of breast","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."}],"pipeline":[],"offLabel":[],"totalMarketed":72,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04185935","title":"Molecular Genetics Studies of Cancer Patients and Their Relatives","phase":"","overall_status":"RECRUITING","enrollment_count":999999,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07291752","title":"The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022","phase":"","overall_status":"COMPLETED","enrollment_count":93481,"lead_sponsor_name":"Suez Canal University","has_results":false},{"nct_id":"NCT02402244","title":"Project: Every Child for Younger Patients With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":75000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03892967","title":"Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":50207,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT06157957","title":"Cancer Screening Smoking Cessation AND Respiratory Assessment","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":40000,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT04494945","title":"Identifying and Caring for Individuals With Inherited Cancer Syndrome","phase":"NA","overall_status":"RECRUITING","enrollment_count":27500,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT06995898","title":"The Vanguard Study: Testing a New Way to Screen for Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":24000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04500600","title":"Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13378,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01772771","title":"Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02970045","title":"Norris ORIEN Total Cancer Care","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03739827","title":"Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00505245","title":"New Assessment System in Measuring Symptom Distress in Cancer Patients","phase":"","overall_status":"RECRUITING","enrollment_count":6500,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT06304168","title":"Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study","phase":"","overall_status":"RECRUITING","enrollment_count":6150,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02310503","title":"Spanish Registry of Mohs Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Fundación Academia Española de Dermatología","has_results":false},{"nct_id":"NCT00026884","title":"Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease","phase":"","overall_status":"RECRUITING","enrollment_count":5950,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06835218","title":"PROCARE - PROstate Cancer Real World Evidence Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"UroTrials Company (GmbH)","has_results":false},{"nct_id":"NCT02474160","title":"Collection and Storage of Tissue and Blood Samples From Patients With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Cancer Institute LAO","has_results":false},{"nct_id":"NCT07325006","title":"Impact of Physician Behavior on Cancer Distress","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00991094","title":"Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05248763","title":"Taiwan Cancer Moonshot Project","phase":"","overall_status":"RECRUITING","enrollment_count":4190,"lead_sponsor_name":"Academia Sinica, Taiwan","has_results":false},{"nct_id":"NCT00786656","title":"Community Cancer Centers Pilot Patient Survey","phase":"","overall_status":"COMPLETED","enrollment_count":3955,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00082745","title":"Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3885,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05112614","title":"Role of Gut Microbiome in Cancer Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05564377","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04955808","title":"Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery","phase":"","overall_status":"SUSPENDED","enrollment_count":2400,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01970254","title":"Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":2206,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05364086","title":"An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2100,"lead_sponsor_name":"University of Rochester NCORP Research Base","has_results":false},{"nct_id":"NCT04871542","title":"Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":2062,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT07126496","title":"A Virtual Community Health Educator for Increasing Clinical Trial Referrals Among Cancer Patients and Their Caregivers","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02280161","title":"Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT00488878","title":"Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07131007","title":"Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT07443761","title":"Patients Undergoing Pancreatic Surgery at the Antwerp University Hospital.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT06295965","title":"Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT04387656","title":"NCI COVID-19 in Cancer Patients, NCCAPS Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1877,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04475640","title":"Cancer Genetic Testing in Ethnic Populations","phase":"NA","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03313492","title":"Modifying Young Adult Skin Cancer Risk and Protective Behaviors","phase":"NA","overall_status":"COMPLETED","enrollment_count":1746,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05132842","title":"Cannabis Use Patterns Among Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1568,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT05179486","title":"Molecular Epidemiology of Biliary Tree Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04654208","title":"Swedish Ibrance Registries Insights (SIRI)","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04068649","title":"Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02152254","title":"Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1362,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05455606","title":"Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1284,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT04447222","title":"Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1242,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}